Sanofi will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, CT, for $650 million upfront and as much as $100 million based on certain development milestones. The acquisition, subject to customary regulatory approvals, is expected to close in 3Q17.   Protein Sciences received approval from the FDA in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV), which is the only recombinant protein-based flu vaccine approved by the FDA.    &#...